Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jan-Feb;9(1):153-5.

Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer

P Vennin  1 , J P Peyrat, J Bonneterre, M M Louchez, A G Harris, A Demaille
Affiliations
  • PMID: 2539768

Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer

P Vennin et al. Anticancer Res. 1989 Jan-Feb.

Abstract

Sixteen post-menopausal patients with advanced breast cancer were treated with a long acting somatostatin analogue, SMS 201-995 (Sandostatin): 0.1 mg bid sub-cutaneously. The dose was chosen on the basis of efficiency in acromegaly treatment. SMS 201-995 activity was evaluated assaying Insulin Growth Factor 1 (IGF1) plasma concentration. A merely partial IGF1 decrease was noted. To be evaluable for response, patients had to be treated for at least 30 days. Among the 14 evaluable patients, we observed no response to SMS 201-995. However, we noted tumor stabilization in 3 patients after a 90 days treatment period. Side-effects were very mild. This first report on SMS 201-995 treatment of breast cancer suggests that further studies evaluating the effect of other modes of administration or drug association should be warranted.

PubMed Disclaimer

Publication types

LinkOut - more resources